NCT03984825View on ClinicalTrials.gov

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

August 16, 2019

Study Completion Date

August 16, 2019

Conditions
HIV Infections
Interventions
DRUG

GSK3640254

GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.

DRUG

Portia

Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY